Thymoquinone loaded on chitosan nanoparticles alleviated the consequences of cryptosporidiosis infection in a murine model: Evidence from parasitological, histopathological, immunohistochemical, and immunological studies

Bibliographic Information
Authors: Ali A.A.; El-Wakil E.S.; Al-Attar A.-S.R.; Fawzy M.; Samy A.; Eldin Z.E.; Al-Megrin W.A.I.; Nazeer J.T.
Journal: PLOS ONE
Publisher: Public Library of Science
Publication Date: 30 May 2025
Volume / Issue: Volume 20 / Issue 2026-05-05 00:00:00
Article No.: e0325077
ISSN: 19326203
DOI: 10.1371/journal.pone.0325077
Scopus: View on Scopus
PubMed: 40446176
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Ali A.A., Pathology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt; El-Wakil E.S., Department of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt; Al-Attar A.-S.R., Pathology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt; Fawzy M., Pathology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt; Samy A., Pathology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt; Eldin Z.E., Materials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Beni-Suef, Egypt; Al-Megrin W.A.I., Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; Nazeer J.T., Department of Medical Parasitology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Background Cryptosporidiosis, a parasitic zoonosis caused by the genus Cryptosporidium (C.), currently lacks a vaccine or fully effective treatment. Nitazoxanide (NTZ), the only medication approved by the US Food and Drug Administration for treating cryptosporidiosis, exhibits limited efficacy in immunosuppressed hosts. Thymoquinone (THQ), the active component of Nigella sativa, possesses immunomodulatory, antitumor, hepatoprotective, antioxidant, antimicrobial, and antiprotozoal properties. This study evaluated the therapeutic effects of THQ alone or loaded onto chitosan nanoparticles (CsNPs) against Cryptosporidium parvum infection compared to NTZ. Methods Chitosan nanoparticles were synthesized and characterized using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), zeta potential analysis, and scanning electron microscopy. The cytotoxicity of CsNPs, THQ/CsNPs, and NTZ/ CsNPs was evaluated on HT-29 cells. Mice were divided into seven groups to assess treatment efficacy through parasitological analysis of oocyst shedding, histopathological examination of intestinal, hepatic, and splenic tissues, immunohistochemical analysis using cyclin D1 staining of intestinal tissue, and immunological analysis measuring IFN-γ and IL-10 cytokine levels. Additionally, pharmacokinetic profiles of THQ and NTZ in free and nanoparticle-loaded forms were analyzed. Results XRD confirmed changes in peak position, shape, and intensity following the loading of THQ and NTZ into CsNPs. FTIR spectra demonstrated distinct differences in peak patterns between loaded nanoparticles and individual components, confirming successful drug encapsulation. Moreover, cytotoxicity studies showed dose-dependent effects on cell viability, with NTZ/CsNPs exhibiting the highest cytotoxicity. Regarding oocyst shedding reduction, THQ demonstrated greater efficacy than NTZ (77% vs. 54%), which was further enhanced when loaded onto CsNPs (89% for THQ/CsNPs vs. 78% for NTZ/CsNPs). Histopathological analysis revealed the restoration of structural alterations in intestinal, hepatic, and splenic tissues in treated groups. Cyclin D1 immunohistochemical staining showed a significant reduction in immunoreactivity in the THQ/CsNP-treated group compared to other treatments. Furthermore, immune responses were modulated by nanoparticle therapies, with significantly lower IFN-γ levels and higher IL-10 levels in treated groups. Pharmacokinetic analysis demonstrated that CsNP formulations significantly improved drug bioavailability by achieving higher peak plasma concentrations (Cmax), earlier time to peak concentration (Tmax), and prolonged half-life (t1/2) compared to free drugs. Conclusion Thymoquinone demonstrated significant potential as an anti-cryptosporidiosis therapeutic agent, with enhanced efficacy when loaded onto chitosan nanoparticles. Chitosan-based nanoparticle formulations improved the pharmacokinetic profiles of both THQ and NTZ, offering a promising strategy for enhancing drug bioavailability and retention while reducing parasitic burden and modulating immune responses effectively. © 2025 Ali et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Animals; Benzoquinones; Chitosan; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Female; HT29 Cells; Humans; Mice; Nanoparticles; chitosan nanoparticle; cyclin D1; dexamethasone; dexazone; doxorubicin; gamma interferon; interleukin 10; isoflurane; nitazoxanide; thymoquinone; xylene; benzoquinone derivative; nanoparticle; anesthesia; animal cell; animal experiment; animal model; animal tissue; Article; atrophy; body weight; cell viability; controlled study; cytotoxicity; dispersity; drug bioavailability; edema; erythrocyte; field emission scanning electron microscopy; Fourier transform infrared spectroscopy; hepatocyte atrophy; histopathology; HT-29 cell line; human; human cell; hyperplasia; immunohistochemistry; inflammatory cell; Kupffer cell; male; megakaryocyte; microsteatosis; mouse; MTT assay; necrosis; nonhuman; oocyst; photon correlation spectroscopy; rat; scanning electron microscopy; submucosal edema; X ray diffraction; animal; chemistry; disease model; drug effect; drug therapy; immunology; parasitology; pathology
Citation Information
Scopus Citations: 3
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
